Saruparib recapitulates PARP-BRCA synthetic lethality with PARP1-trapping properties limiting its cytotoxicity

The original concept of PARP synthetic lethality proposes that loss of poly(ADP-ribose) polymerase (PARP) activity selectively kills homologous recombination (HR)-deficient cells. However, clinically approved PARP1/2 inhibitors (PARPis) are used at exposures exceeding those required for catalytic inhibition. At these doses, PARP trapping is cytotoxic to HR-proficient cells and limits the therapeutic window in HR-deficient cancers. Saruparib has been developed as a PARP1-selective inhibitor to reduce PARP2-associated toxicity; yet its PARP1-trapping properties remain incompletely characterized. Here, we show that saruparib exhibits trapping properties distinct from those of conventional PARPis. It causes minimal cytotoxicity in HR-proficient cells and remains minimally toxic in XRCC1-deficient cells, which are highly sensitive to trapping-associated cytotoxicity induced by conventional PARPis. Although methyl methanesulfonate, which induces extensive base damage, increases saruparib-induced PARP1 trapping and cytotoxicity, the overall trapping-associated cytotoxic response is weaker than that induced by olaparib and shows little further dose-dependent increase once catalytic PARP1 inhibition is achieved. Biochemical measurements demonstrated that PARP1-DNA complexes formed in the presence of saruparib are less stable than those in the presence of olaparib or talazoparib. Notably, saruparib potently kills BRCA1-, BRCA2-, and PALB2-deficient cells at concentrations sufficient for near-maximal catalytic inhibition, without a corresponding increase in cytotoxicity in HR-proficient cells. Thus, saruparib combines potent HR-deficient-selective cytotoxicity with limited PARP1 trapping and associated toxicity. Consequently, saruparib closely recapitulates the PARP-BRCA synthetic lethality while sparing HR-proficient cells, providing a mechanistic framework for its rational clinical use.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.17.767429
Primary Topic
PARP inhibition in cancer therapy
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Saruparib recapitulates PARP-BRCA synthetic lethality with PARP1-trapping properties limiting its cytotoxicity

Shingo Dan, Sho Isoyama, Kenjiro Sawada, Yves Pommier et al.
bioRxiv (Cold Spring Harbor Laboratory)
PARP inhibition in cancer therapy
preprint

Saruparib recapitulates PARP-BRCA synthetic lethality with PARP1-trapping properties limiting its cytotoxicity

Shingo Dan, Sho Isoyama, Kenjiro Sawada, Yves Pommier, Erina Kusakabe, Kaho Utsunomiya, Ryo Kamata, Hiroyuki Sasanuma, Junko Murai, Hiroshi Onji, Takashi Sugiyama, Tomohiro Iguchi, Koji Hirota, Shiho Nakano
preprint en

Abstract

The original concept of PARP synthetic lethality proposes that loss of poly(ADP-ribose) polymerase (PARP) activity selectively kills homologous recombination (HR)-deficient cells. However, clinically approved PARP1/2 inhibitors (PARPis) are used at exposures exceeding those required for catalytic inhibition. At these doses, PARP trapping is cytotoxic to HR-proficient cells and limits the therapeutic window in HR-deficient cancers. Saruparib has been developed as a PARP1-selective inhibitor to reduce PARP2-associated toxicity; yet its PARP1-trapping properties remain incompletely characterized. Here, we show that saruparib exhibits trapping properties distinct from those of conventional PARPis. It causes minimal cytotoxicity in HR-proficient cells and remains minimally toxic in XRCC1-deficient cells, which are highly sensitive to trapping-associated cytotoxicity induced by conventional PARPis. Although methyl methanesulfonate, which induces extensive base damage, increases saruparib-induced PARP1 trapping and cytotoxicity, the overall trapping-associated cytotoxic response is weaker than that induced by olaparib and shows little further dose-dependent increase once catalytic PARP1 inhibition is achieved. Biochemical measurements demonstrated that PARP1-DNA complexes formed in the presence of saruparib are less stable than those in the presence of olaparib or talazoparib. Notably, saruparib potently kills BRCA1-, BRCA2-, and PALB2-deficient cells at concentrations sufficient for near-maximal catalytic inhibition, without a corresponding increase in cytotoxicity in HR-proficient cells. Thus, saruparib combines potent HR-deficient-selective cytotoxicity with limited PARP1 trapping and associated toxicity. Consequently, saruparib closely recapitulates the PARP-BRCA synthetic lethality while sparing HR-proficient cells, providing a mechanistic framework for its rational clinical use.

bioRxiv (Cold Spring Harbor Laboratory)
National Institutes of Health (US), Tokyo Metropolitan Institute of Medical Science (JP), Japanese Foundation For Cancer Research (JP), Ehime University (JP), Premier Institute for Advanced Studies, Ehime University (JP), Proteo-Science Center, Ehime University (JP), Tokyo Metropolitan University (JP)
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon